US incentive scheme for neglected diseases: a good idea gone wrong?
PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionThe US priority review voucher scheme was intended to encourage drug companies to invest in treatments for neglected diseases. But nearly seven years on, the author reports, there is little demonstrated innovation and evidence that the benefits are not going where they were intended.
CitationDoshi, P. (2014). US incentive scheme for neglected diseases: a good idea gone wrong? BMJ, 349. DOI: 10.1136/bmj.g4665
priority review vouchers
United States. Food and Drug Administration
Neglected Diseases--drug therapy
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6607